ASSOCIATION OF CLINICAL PARAMETERS AND INTERFERON ALPHA/BETA RECEPTOR SUBUNIT 2 IN HCV PATIENTS RESISTANT TO INTERFERON THERAPY

Authors

  • Gulshan Ara Trali Department of Biochemistry, HITEC-Institute of Medical Sciences Taxila Cantt., Pakistan
  • Ambreen Javed Department of Biochemistry, HITEC-Institute of Medical Sciences Taxila Cantt., Pakistan
  • Alia Sadiq Department of Biochemistry, HITEC-Institute of Medical Sciences Taxila Cantt., Pakistan
  • Abdul Khaliq Naveed CMH Lahore Medical College, Lahore, Pakistan

DOI:

https://doi.org/10.69656/pjp.v14i1.197

Abstract

Background: Interferon therapy is an expensive treatment for hepatitis C virus (HCV) which may results in undesirable side effects. About 50% of chronic HCV patients do not respond to interferon (IFN) therapy for unknown reasons. It is important to determine the association of clinical parameters with IFNAR-2 in HCV patients, resistant to IFN therapy. Methods: HCV genotype 3 patients were included in study (n=20, between 30–60 age group) and categorized into two groups, the experimental group including patients responding to interferon treatment and the control group consisting of interferon resistant patients. Blood samples and Liver biopsy specimens were collected from all HCV patients. Clinical parameters included in the study were (i) pre-biopsy tests (platelet count, bleeding time, prothrombin time) (ii) HCV viral genotype 3 (iii) HCV-RNA and (iv) liver functions (ALT, ALP, and bilirubin). Molecular investigations were carried out by using PCR and gel electrophoresis to identify IFNAR-2 in all HCV genotype 3 patients. Results: Experimental results from clinical testing of non-responder (resistant) group, showed significantly increased ALT level (64.13±17.48 U/L) as compared to responder group (46±6.3 U/L). Hemoglobin (Hb) level was also found significantly increased in non-responder group (12.9±1.8 g/dL) in comparison with responder group (10.3±0.48 g/dL). Further molecular testing revealed that all interferon resistant patients showed the presence of IFNAR-2. Conclusion: Experimental observations revealed that non-responder HCV genotype 3 patients showed elevated ALT and Hb levels and presence of IFNAR-2 protein. Therefore, experimental results of this study signify the importance of monitoring clinical parameters in parallel with IFN therapy in non-responder HCV patients.

Keywords: HCV, Genotype, IFN therapy, Liver Function tests

Pak J Physiol 2018;14(1):33–6

Downloads

Download data is not yet available.

References

1. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic Hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012;205:763–71.
2. Wilder J, Patel K. A review of the natural history of chronic hepatitis C infection. North Am J Med Sci 2014;7(1):1–7.
3. Zhu RX, Seto WK, Lai CL, Yuen MF. Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver 2016;10(3):332–9.
4. Michael CK. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma 2014;1:115–25.
5. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1 Suppl): S58–68.
6. Razzaq Z, Malik A. Viral load is associated with abnormal serum levels of micronutrients and glutathione and glutathione-dependent enzymes in genotype 3 HCV patients. BBA Clin 2014;2:72–8.
7. Sosa-Jurado F, Hernández-Galindo VL, Meléndez-Mena D, Mendoza-Torres MA, Martínez-Arroniz FJ, Vallejo-Ruiz V, et al. Detection of hepatitis C virus RNA in saliva of patients with active infection not associated with periodontal or liver disease severity. BMC Infect Dis 2014;14:72.
8. Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015;7:2676–80.
9. Ringehan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci 2017;372(1732). pii: 20160274.
10. de Weerd NA, Nguyen T. The interferons and their receptors–distribution and regulation. Immunol Cell Biol 2012;90:483–91.
11. Nagaoki Y, Imamura M, Aikata H, Daijo K1, Teraoka Y1, Honda F, et al. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One 2017;12(8):e0182710d.
12. Ji F, Zhang S, Deng H, Li Z. Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: Further evidence in decompensation cirrhosis. J Hepatol 2013;58:1262–4.
13. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015;7(12):1617–31.
14. Pol S, Corouge M, Vallet-Pichard A. Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med 2016;8:21–6.
15. Tachi Y, Hirai T, Kojima Y, Ishizu Y, Honda T, Kuzuya T, et al. Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response. Liver Int 2018;38(1):59–67.
16. Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf) 2016;4(1):24–9.
17. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US. Veterans with HCV. Hepatology 2014;60(1):98–105.
18. Kanwal S, Mahmood T. Hepatitis C virus resistance to interferon therapy: an alarming situation. Cent Eur J Biol 2014;9:1155–67.
19. Brjalin V. Chronic hepatitis C: predictors of treatment response in Estonian patients [Internet] [Thesis]. 2014. Faculty of Medicine, University of Tartu, Estonia. Available from: http://dspace.ut.ee/handle/10062/44020
20. Mustafa M, Hussain S, Qureshi S, Malik SA, Kazmi AR, Naeem M. Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus-infected patients. BMC Gastroenterol 2012;12:117.
21. Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection—tipping the balance. J Leukoc Biol 2014;96(4):535–48.
22. Yang C, Zhao X, Sun D, Chong C, Pan Y, Chi X, et al. Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol 2016;13(1):94–102.
23. Frodsham AJ, Zhang L, Dumpis U, Taib NA, Best S, Durham A, et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci USA 2006;103(24):9148–53.
24. Zhao J, Fan YC, Sun FK, Zhao ZH, Wang LY, Hu LH, et al. peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection. J Interferon Cytokine Res 2013;33(8):405–14.
25. Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One 2014;9(9):e108616.
26. Taniguchi H, Iwasaki Y, Takahashi A, Shimomura H, Moriya A, Yu PC, et al. Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C. Intervirology 2007;50:32–9.
27. Friborg J, Lin B, Chen C, McPhee F. Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines. Virology 2013;444(1-2):384–93.
Pak J Physiol 2018;14(1)

Downloads

Published

31-03-2018

How to Cite

1.
Trali GA, Javed A, Sadiq A, Naveed AK. ASSOCIATION OF CLINICAL PARAMETERS AND INTERFERON ALPHA/BETA RECEPTOR SUBUNIT 2 IN HCV PATIENTS RESISTANT TO INTERFERON THERAPY. Pak J Phsyiol [Internet]. 2018 Mar. 31 [cited 2024 Nov. 23];14(1):33-6. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/197

Issue

Vol. 14 No. 1 (2018): Pakistan Journal of Physiology

Section

Original Article

License

Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, projected, cited and quoted with full reference of, and acknowledgement to the author(s) and the PJP. The contents are published with an international CC-BY-ND-4.0 License.